Reduction of Pain Episodes and Prothrombotic Activity in Sickle Cell Disease by Dietary n-3 Fatty Acids

Summary

The effects of dietary n-3 fatty acids (n-3FAs) on the frequency of pain episodes and ex vivo blood tests of thrombosis have been evaluated in patients with sickle cell disease (SCD) utilizing a doubleblind, olive oil-controlled clinical trial. Dietary n-3FA therapy (0.1 g/kg/d) was provided as menhaden fish oil (0.25 g/kg/d) containing 12% eicosapentaenoic acid (EPA), and 18% docosahexaenoic acid (DHA). Within 1 month dietary n-3FAs exchanged with n-6FAs in plasma and erythrocyte membrane phospholipids (p <0.01 in all cases).

Treatment with dietary n-3FAs for 1 year reduced the frequency of pain episodes requiring presentation to the hospital from 7.8 events during the preceding year to 3.8 events/year (p <0.01; n = 5). By contrast, subjects receiving control dietary olive oil (n = 5) experienced 7.1 pain events/year, compared to 7.6 during the previous year (p >0.4). The reduction in episodes in n-3FA-treated subjects was also significant when compared to control subjects (p <0.01). Dietary n-3FA therapy was not associated with hemorrhagic, gastrointestinal or other adverse effects.

Compared to 10 asymptomatic African-American controls, sickle cell subjects demonstrated significantly increased pretreatment: 1) flow cytometric expression of platelet membrane P-selectin (CD62p; p <0.01) and annexin V binding sites (p = 0.02); 2) plasma levels of platelet-specific secretory proteins platelet factor 4 (PF4) and -thromboglobulin (TG) (p <0.01 in both cases); 3) plasma products of thrombin generation, prothrombin fragment 1.2 (F1.2) and thrombin:antithrombin (TAT) complex (p <0.01 in both cases); and 4) plasma levels of thrombolytic products, D-dimer and plasmin:antiplasmin (PAP) complex (p <0.01 in both cases). Treatment with dietary n-3FAs concurrently decreased plasma levels of F1.2, D-dimer, and PAP (p <0.05, compared to olive oil controls), implying that the reduction in pain events was related to n-3FA-dependent inhibition of thrombosis. We conclude that dietary n-3FAs reduce the frequency of pain episodes perhaps by reducing prothrombotic activity in sickle cell disease.

Key words

Sickle cell - thrombosis - n-3 fatty acids

• References

• 1 Diggs LW, Ching RE. Pathology of sickle cell anemia. South Med J 1934; 27: 839-49.
• 2 Diggs LW, Vorder Bruegge CF. Vascular occlusive mechanisms in sickle cell disease. J Nat Med Assoc 1954; 46: 46-9.
• 3 Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991; 77: 1405-14.
• 4 Leslie J, Langler D, Serjeant GR, Serjeant BE, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol 1975; 30: 159-66.
• 5 Rickles FR, O’Leary DS. Role of coagulation system in pathophysiology of sickle cell disease. Arch Intern Med 1974; 133: 635-41.
• 6 Green D, Scott JP. Is sickle cell crisis a thrombotic event?. Am J Hematol 1986; 23: 317-21.
• 7 Devine DV, Kinney TR, Thomas PF, Rosse WF, Greenberg CS. Fragment d-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood 1986; 68: 317-9.
• 8 Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992; 81: 539-44.
• 9 Francis R, Patch J, McGehee W, Crout F. Elevated prothrombin F1.2 fragment in sickle cell disease: further evidence for activation of coagulation in the steady state. Blood 1990; 76: 161a.
• 10 Richardson SGN, Matthews KB, Stuart J. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979; 41: 95-103.
• 11 Alkjaesig N, Fletcher A, Joist H, Chaplin Jr H. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med 1976; 88: 440-9.
• 12 Leichtman DA, Brewer GJ. Elevated plasma levels of fibrinopeptide A during sickle cell anemia pain crisis – evidence for intravascular coagulation. Am J Hematol 1978; 5: 183-90.
• 13 Phillips G, Mitchell LB, Pizzo SV. Defective release of tissue plasminogen activator in patients with sickle cell anemia. Am J Hematol 1988; 29: 52-3.
• 14 Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973; 82: 44-53.
• 15 Grupp RA, Glueck HI, Granger SM, Miller MA. Platelet function in sickle cell anemia. Thromb Res 1977; 10: 325-55.
• 16 Stuart MJ, Stockman JA, Oski FA. Abnormalities of platelet aggregation in the vaso-occlusive crisis of sickle-cell anemia. J Pediatr 1974; 85: 629-32.
• 17 Mehta P, Mehta J. Abnormalities of platelet aggregtion in sickle cell disease. J Pediatr 1980; 96: 209-13.
• 18 Buchanan GR, Holtkamp CA. Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 1983; 54: 595-603.
• 19 Tomer A, Harker LA, Kasey S, Eckman JR. Thrombosis in sickle cell disease. J LCM. in press 2001
• 20 Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial interactions. Curr Opinion Hematol 1996; 3: 118-24.
• 21 Davis HR, Bridenstine RT, Vesselinovitch D, Wissler RW. Fish oil inhibits development of atherosclerosis in rhesus monkeys. Arteriosclerosis 1987; 7: 441-9.
• 22 Goodnight SH, Harris WS, Connor WE. The effect of dietary omega-3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981; 58: 880-5.
• 23 Landymore RW, Kinley CE, Cooper JH, MacAulay M, Sheridan B, Cameron C. Cod-liver oil in the prevention of intimal hyperplasia in autogenous vein grafts used for arterial bypass. J Thorac Cardiovasc Surg 1985; 89: 351-7.
• 24 Hartog JM, Lamers JMJ, Essed CE, Schalkwijk WP, Verdouw PD. Does platelet aggregation play a role in the reduction in localized intimal proliferation in normolipidemic pigs with fixed coronary artery stenosis fed dietary fish oil?. Atherosclerosis 1989; 76: 79-88.
• 25 Dehmer GJ, Popma J, Van den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988; 319: 733-40.
• 26 Milner MR, Gallino RA, Leffingwell A, Pichard AD, Brooks-Robinson S, Rosenberg J, Little T, Lindsay Jr J. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1989; 64: 294-9.
• 27 Roy L, Bairati I, Meyer F, Genest MB. Double-blind randomized controlled trial of fish oil supplements in the prevention of restenosis after coronary angioplasty. Circulation 1991; 84 (Suppl II) II-365-II-365.
• 28 Grigg LE, Kay TWH, Valentine PA, Larkins R, Flower DJ, Manolas EG, O’Dea K, Sinclair AJ, Hopper JL, Hunt D. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol 1989; 13: 665-72.
• 29 Dalen JE, Hirsh J. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995; 108: 225S-522S.
• 30 Antiplatelet Trialists’ Collaboration.. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
• 31 CAPRIE Steering Committee.. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of aeschmia. Lancet 1996; 348: 1329-39.
• 32 Salvaggio Je, Arnold CA, Banov CH. Long-term anticoagulation in sickle-cell disease. N Engl J Med 1963; 269: 182-6.
• 33 Chaplin Jr H, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disese pain crises. Thromb Haemost 1980; 43: 218-21.
• 34 Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediat 1983; 102: 781-4.
• 35 Zago M, Costa F, Ismel S, Tone L, Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984; 72: 61-4.
• 36 Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984; 51: 303-306.
• 37 Osamo ND, Photiades DP, Famadu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1998; 66: 102-7.
• 38 Leslie J, Langler D, Serjeant GR, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Brit Med J 1975; 30: 159-66.
• 39 McTavish D, Faulds D, Goa KL. Ticlopidine: An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-59.
• 40 Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-41.
• 41 Harker LA, Hanson SR. Experimental strategies for assessing antithrombotic benefits and hemorrhagic risks of novel antithrombotic agents. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara A, Loscalzo J. eds. Marcel Dekker; New York: 1997. pp 29-48.
• 42 Harker LA, Kelly AB, Hanson SR, Krupski W, Bass A, Osterud B, Fitz Gerald GA, Goodnight SH, Connor WE. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 1993; 87: 1017-29.
• 43 Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978; 2: 117-9.
• 44 Goodnight SH. Fish oil and vascular disease. Trends Cardiovasc Med 1992; 1: 112-6.
• 45 Hansen JB, Olsen JO, Wilsgard L, Osterud B. Effects of dietary supplementation with cod liver oil on monocyte thromboplastin synthesis, coagulation and fibrinolysis. J Intern Med Suppl 1989; 225: 133-9.
• 46 Weiner BH, Ockene IS, Levine PH. et al. Inhibition of atherosclerosis by codliver oil in a hyperlipidemic swine model. N Engl J Med 1986; 315: 841-6.
• 47 DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzerini G, Maffei S, Cerri M, Salvatore L, Weksler B. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990; 82: 428-38.
• 48 Von Schacky C. The role of n-3 fatty acids in prophylaxis and treatment of occlusive vascular disease. Focus on Hemostasis 1992; 2: 1-4.
• 49 Lee TH, Hoover RL, William JD, Sperling RI, Ravalese III J, Spur BW, Robinson DR, Corey EJ, Lewis RA, Austin KF. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985; 312: 1217-24.
• 50 Schick PK, Wojenski CM, Walker J. The effects of olive oil, hydrogenated palm oil, and n-3 fatty acid-enriched diets on megakaryocytes and platelets. Arteriosclerosis Thromb 1993; 13: 84-9.
• 51 Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arteriosclerosis Thromb 1992; 12: 1475-87.
• 52 Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation- dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
• 53 Nieuwenhuis HK, van Oosterhout JJG, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: Evidence that a secreted 53,000 molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987; 70: 838-45.
• 54 Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane; studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
• 55 Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. J Biol Chem 1990; 265: 17420-3.
• 56 Bevers EM, Comfurius P, Zwaal RFA. Platelet procoagulant activity: Physiological significance and mechanisms of exposure. Blood Rev 1991; 5: 146-54.
• 57 Lin DS, Ilias AM, Connor WE. et al. Composition and biosynthesis of sterols in selected marine phytoplankton. Lipids 1982; 17: 818-24.
• 58 Smith DL, Willis AL, Nguyen N, Conner D, Zahedi S, Fulks J. Eskimo plasma constituents, dihomo-gamma-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid inhibit the release of atherogenic mitogens. Lipids 1989; 24: 70-5.
• 59 Rapp JH, Connor WE, Lin DS, Porter JM. Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques. Arteriosclerosis Thromb 1991; 11: 903-11.
• 60 Reis GJ, Boucher TM, Sipperly ME. et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989; 2: 177-81.
• 61 Frolich JC, Von Schacky C. Fish, Fish Oil and Human Health. Munich, Germany: Zuckschwerdt; 1992
• 62 Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: Diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
• 63 Liu HW, Wong KL, Lin CK, Wong WS, Tse PWT, Chan GTC. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol 1989; 72: 229-34.
• 64 Melissari E, Kakkar VV. Congenital severe protein C deficiency in adults. Br J Haematol 1989; 72: 222-8.
• 65 Marcus AJ. Editor’s commentary: the role of n-3 fatty acids in prophylaxis and treatment of occlusive vascular disease. Focus on Hemostasis 1992; 2: 1-4.
• 66 Von Schacky C. Prophylaxis of atherosclerosis with marine omega-fatty acids: a comprehensive strategy. Ann Intern Med 1987; 107: 890-9.
• 67 Terano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamura Y, Kumagai A. Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983; 46: 321-31.
• 68 Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985; 26: 1015-35.
• 69 Lehr HA, Menger MD, Nolte D, Messmer K. Favorable effects of dietary fish oil on capillary perfusion homogeneity after ischemia and reperfusion. Transplant Proc 1991; 23: 2356-8.
• 70 Harlan JM, Lie DY. Adhesion: Its Role in Inflammatory Disease. New York: W. H. Freeman; 1991
• 71 Conkie JA, McCall F, Walker ID, Davidson JF. Evaluation of an automated prothrombin assay using a chromogenic substrate. Haemostasis 1984; 14: 307-7.
• 72 Lehr H-A, Hübner C, Finckh B, Nolte D, Beisiegel U, Kohlschütter A, Messmer K. Dietary fish oil reduces leukocyte/endothelium interaction following systemic administration of oxidatively modified low density lipoprotein. Circulation 1991; 84: 1725-31.
• 73 Lehr H-A, Hübner C, Nolte D, Kohlschütter A, Messmer K. Dietary fish oil blocks the microcirculatory manifestations of ischemia-reperfusion injury in striated muscle in hamsters. Proc Natl Acad Sci USA 1991; 88: 6726-30.
• 74 Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989; 31: 237-41.
• 75 Belluzzi A, Bringola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996; 334: 1557-60.
• 76 Skoldstam L, Borjesson O, Kjallman A, Seiving B, Akesson B. Effect of six months of fish oil supplementation in stable rheumatoid arthritis. A double-blind, controlled study. Scand J Rheumatol 1992; 21: 178-185.
• 77 Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994; 37: 824-9.